Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver

A technology of quinoline quinone and fatty liver, which is applied in the medical field and can solve the problems that the drugs for fatty liver cannot achieve results.

Inactive Publication Date: 2003-11-12
ZHUCHENG HAOTIAN PHARMA
View PDF1 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, these drugs for the prevention and treatment of fatty liver can not yet achieve satisfactory results. Therefore, there is an urgent need in this field to develop new safe and effective fatty liver treatment and preventive drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver
  • Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Establishment of a method for the detection of pyrroloquinoline quinone

[0049] In the present invention, two methods of NBT chromogenic method and FPLC are used to detect the content of pyrroloquinoline quinone.

[0050] The NBT method uses pyrroloquinoline quinone to make NBT (nitro blue tetrazolium chloride) chemical color development in alkaline solution, and can quantitatively detect the content of pyrroloquinoline quinone in the mixture (more than 10ng can be detected pyrroloquinoline quinone).

[0051] The specific operation is as follows: add 400ul water containing 25ul bovine serum albumin (40mg / ml) to the pyrroloquinoline quinone sample or standard substance to be tested, add 1.6ml assay buffer (NBT+1.6M glycine buffer) for each sample, Mix well. Incubate at 37°C for 45 minutes in the dark, and measure the light absorption value at 530 nm. Make standard curve accordingly, calculate the content of pyrroloquinoline quinone in the sample to be tested.

[005...

Embodiment 2

[0054] Preparation of pyrroloquinoline quinone

[0055] A. Fermentation of pyrroloquinoline quinone

[0056] A common method for obtaining pyrroloquinoline quinone is to use methanolophilic bacteria to synthesize pyrroloquinoline quinone, and obtain pyrroloquinoline quinone by fermentation and separation. Strains such as Methylophagathalassica (ATCC #33145) can be used directly, or improved strains provided by PQQ production can also be used. The specific method is as follows.

[0057] Methylophaga thalassica (ATCC#33145), by changing the concentration of methanol (0.1-7%), screened a strain, the expression of PQQ from 0.5mg / L to 2.0mg / L, this strain was named GCpqq303.

[0058] Training time

(sky)

PQQ output

(mg / L)

FeCl 3 content

(%)

PQQ output

(mg / L)

MgSO 4 content

(%)

PQQ output

(mg / L)

1-7

≈0

0

0.04

0

0.07

8

0.3

0.005

...

Embodiment 3

[0062] Therapeutic and preventive effects of pyrroloquinoline quinone on alcoholic fatty liver

[0063] The Kunming mice were divided into 10 groups, 12 in each group, half male and half male, with an average body weight of 25 grams. The grouping situation is shown in the table below, and the specific experimental method is described as follows: Alcohol gavage is 0.25ml / day of white wine with an alcohol concentration of 56%, for 15 days, and a mouse model of acute alcoholic fatty liver is established. PQQ is divided into a treatment group and a prevention group. The treatment group is treated by intragastric administration or intraperitoneal injection for 30 days after the fatty liver model is established; PQQ was carried out for 30 days to determine the preventive effect of PQQ on fatty liver.

[0064] Group No

group name

illustrate

1

Fatty liver model

alcohol gavage

2

PQQ treatment group

Fatty liver model, intraperitoneal in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention refers to a medicine combination which can cure and prevent the fatty liver in mammal, especially in human and endotherm. It contains a safe and effective amount of pyrrole & quinoline quinone and/or its acceptable salt and/or ester in pharmacy as the active component, and the acceptable carrier in pharmacy. It has a remarkably curative effect on the fatty liver,

Description

technical field [0001] The present invention relates to the medical field, and more specifically, relates to a pharmaceutical composition for treating and preventing fatty liver in mammals, especially humans and warm-blooded animals. The composition contains pyrroloquinoline quinone (or its salt, ester) as an active ingredient. Background technique [0002] Fatty liver is a pathological state in which multiple etiologies cause excessive lipid accumulation in liver cells. Depending on the etiology, the lipids that accumulate in the liver can be triglycerides, phospholipids, glycolipids, or sterol esters. In the development of fatty liver, especially steatohepatitis and liver fibrosis, the body's immune status, nutritional factors, genetic background, lifestyle, age and gender all play a very important role. condition factor. The summary is as follows: Nutritional factors Malnutrition, obesity, total parenteral nutrition, lack of fat-dispelling substances in the body. Chem...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A23L33/00A61K31/4738A61P1/16
Inventor 顾建新陈淳陈晓宁张思沈爱国张勇
Owner ZHUCHENG HAOTIAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap